Results 11 to 20 of about 66,840 (318)

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.

open access: yesJournal of the American Medical Association (JAMA), 2023
Importance It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate COVID-19.
S. Naggie   +248 more
semanticscholar   +1 more source

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.

open access: yesJournal of the American Medical Association (JAMA), 2021
Importance Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit. Objective To determine whether ivermectin is an efficacious treatment for mild COVID-19.
Eduardo López-Medina   +18 more
semanticscholar   +1 more source

Effect of Early Treatment with Ivermectin among Patients with Covid-19

open access: yesNew England Journal of Medicine, 2022
Background The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome ...
Gilmar Reis   +26 more
semanticscholar   +1 more source

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.

open access: yesNew England Journal of Medicine, 2022
BACKGROUND Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. METHODS In this phase 3, double-blind,
C. Bramante   +36 more
semanticscholar   +1 more source

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial.

open access: yesJAMA Internal Medicine, 2022
Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed.
Steven Chee-Loon Lim   +25 more
semanticscholar   +1 more source

Is the antiparasitic drug ivermectin a suitable candidate for the treatment of epilepsy?

open access: yesEpilepsia, 2023
There are only a few drugs that can seriously lay claim to the title of “wonder drug,” and ivermectin, the world's first endectocide and forerunner of a completely new class of antiparasitic agents, is among them.
W. Löscher
semanticscholar   +1 more source

In vitro larvicidal activity of ivermectin and povidone-iodine against Oestrus ovis.

open access: yesPLoS ONE, 2021
PurposeTo assess the in vitro larvicidal activity of ivermectin and povidone-iodine (PVP-I) against Oestrus ovis, the most frequent cause of external ophthalmomyiasis.MethodsL1 O.
Giuseppe D'Amico Ricci   +6 more
doaj   +2 more sources

Ivermectin metabolites reduce Anopheles survival

open access: yesScientific Reports, 2023
Ivermectin mass drug administration to humans or livestock is a potential vector control tool for malaria elimination. The mosquito-lethal effect of ivermectin in clinical trials exceeds that predicted from in vitro laboratory experiments, suggesting ...
Kevin C. Kobylinski   +14 more
doaj   +1 more source

Ivermectin for preventing and treating COVID‐19

open access: yesCochrane Database of Systematic Reviews, 2021
Background Ivermectin, an antiparasitic agent used to treat parasitic infestations, inhibits the replication of viruses in vitro. The molecular hypothesis of ivermectin's antiviral mode of action suggests an inhibitory effect on severe acute respiratory ...
M. Popp   +7 more
semanticscholar   +1 more source

Ivermectin [PDF]

open access: yesReactions Weekly, 2020
EXCLI Journal;Vol.
Heimfarth, Luana   +4 more
  +5 more sources

Home - About - Disclaimer - Privacy